The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Novel treatment agents and how they’re changing the MPN field
Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses novel treatment approaches in myeloproliferative neoplasms (MPNs), drawing focus on JAK inhibitors, including ruxolitinib, fedratinib and pacritinib. Prof. Harrison also highlights the MOMENTUM trial (NCT04173494) evaluating the use of momelotinib for the treatment of myelofibrosis. To conclude, Prof. Harrison discusses the importance of using combination therapy for the treatment of myelofibrosis, and the promise that this approach has for the future of MPN treatment. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Research funding: Celgene, Constellation, Novartis
Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
